News of the FDA’s investigation into the weight loss drug Alli caught parent company GlaxoSmithKline off guard. But in a recent article by Matthew Perrone in The Associated Press, pharma specialist Mark Senak
says it’s the type of action regulated companies should start to expect as the agency moves toward “a more pro-active public health stance.”
FDA Investigation Surprises Global Pharma Giant
Posted on September 11th, 2009 | More Agribusiness · Food & Beverage · Healthcare · Public Affairs
Related Posts
-
The Role of Digital Communications and ‘Pharmacovigilance’
In an article in PharmaVoice, pharma specialist Mark Senak
discusses pharmacovigilance communication and explains why the best digital strategy includes “the concept of a two-way exchange.”Posted on February 3rd, 2012 | More Crisis Communications · Digital & Social Media · Healthcare
-
An Agenda for the 2012 Conventions
While political conventions are “networking on steroids,” they also provide serious business opportunities. The public affairs specialists at VOX Global
, a Fleishman-Hillard company, share a strategy for engagement at the 2012 conventions.Posted on January 31st, 2012 | More CSR · Digital & Social Media · Mobile · Public Affairs · Reputation Management
-
Inside the World of the WEF
The World Economic Forum might be “a dream” for communications and public affairs professionals, but how can it improve? In a PRWeek column, Jack Modzelewski, Fleishman-Hillard president of the Americas, looks at this year’s “biggest thematic set change.”
Posted on January 30th, 2012 | More B2G · Financial Services & Insurance · Public Affairs
